The Effects of Specific tDCS on Cognition in MCI
Launched by ISTANBUL MEDIPOL UNIVERSITY HOSPITAL · Jun 16, 2023
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called transcranial direct current stimulation (tDCS) to see if it can help improve thinking and memory in people with mild cognitive impairment (MCI), particularly those with conditions like Alzheimer’s and Parkinson's disease. MCI is a stage where people may experience noticeable memory changes but not severe enough to be diagnosed with dementia. The trial will involve 120 participants aged between 45 and 80, who will receive either the actual treatment or a placebo (sham control) over 14 days. Participants will undergo various tests to evaluate their cognitive function and brain activity before and after the treatment.
To be eligible for the trial, participants must be literate, diagnosed with MCI related to Parkinson's or Alzheimer’s, and stable on their current medications for at least a month. Importantly, individuals with other neurological or psychiatric conditions, as well as those who have experienced serious head injuries or have significant hearing or vision problems, cannot participate. Throughout the trial, participants can expect to attend up to 10 sessions of stimulation, each lasting 20 minutes, along with regular assessments to track any changes in their cognitive abilities and brain connectivity. This study aims to provide valuable insights into whether tDCS can be an effective tool in slowing cognitive decline in these populations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Providing an informed consent;
- • 2. Literate and between 45-80 years of age;
- • 3. 60 females and 60 males;
- • 4. Diagnosed with PD based on criteria suggested by UK Parkinson's Disease Society, Brain Bank and PD-MCI in accordance with the diagnostic criteria suggestions by Litvan;
- • 5. Diagnosed with aMCI based on diagnosis criteria (CDR\>0.5) suggested by Petersen;
- • 6. On a stable pharmacological treatment minimum for one month with no washout period.
- Exclusion Criteria:
- • Illiterate or education level less than primary school
- • Having an existing and/or prior neurological disease; psychiatric disease or head trauma; and/or irreversible hearing or sight problems or other medical illness (e.g. diabetes mellitus, hypertension);
- • Exhibiting signs of dementia for PD group ;
- • Having medical issues that prevent undergoing fMRI or for tDCS application.
About Istanbul Medipol University Hospital
Istanbul Medipol University Hospital is a leading healthcare institution in Turkey, renowned for its commitment to advanced medical research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its state-of-the-art facilities and a multidisciplinary team of experts to facilitate innovative studies across various medical fields. With a strong emphasis on patient safety and ethical standards, Istanbul Medipol University Hospital strives to contribute to the advancement of medical knowledge and the development of effective treatments, ensuring high-quality care and improved health outcomes for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Antalya, Alanya, Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported